Could Moderna Be a Millionaire-Maker Stock?
2020 has nearly come to an end, and the world is still engulfed in the deadly coronavirus pandemic. Globally, cases have crossed the 64 million mark, and there have been 1.48 million deaths from the virus worldwide. In the U.S. alone, 13.7 million cases have been reported as of Dec. 2, and there have been at least 270,000 deaths. As the number of confirmed cases rises, pharma and biotech companies are working quickly to bring a safe and effective vaccine to market.
The two leading players -- Pfizer (NYSE: PFE) (with its partner, BioNTech (NASDAQ: BNTX)) and Moderna (NASDAQ: MRNA) -- announced positive interim trial results from their vaccine candidates last month. Moderna's results for its COVID-19 vaccine candidate, mRNA-1273, released on Nov. 16, showed that the potential vaccine was 94.5% effective at protecting patients against COVID-19 infection.
It likely comes as no surprise, then, that its stock is up 650% year to date, while the S&P 500 has risen just 13%. mRNA-1273 has a few advantages over Pfizer's potential vaccine. But what else can Moderna offer investors? Let's take a look.
Source Fool.com
